throbber

`

`US 6,926,907 B2
`Page 2
`
`U.S. PATENT DOCUMENTS
`
`12/1985 Hirata et a!. ................ 548/184
`4,562,261 A
`10/1986 Sunshine eta!. ........... 514/277
`4,619,934 A
`................... 424/157
`6/1987 Wu et a!.
`4,676,984 A
`11/1987 Wu et a!.
`................... 424/157
`4,704,278 A
`7/1988 Lukacsko eta!. ........... 514/160
`4,757,060 A
`8/1988 Crawford eta!. ........... 514/219
`4,766,117 A
`11/1988 Lovgren et a!.
`............ 424/468
`4,786,505 A
`10/1990 Lukacsko et a!. ............. 424/10
`4,965,065 A
`8/1991 Lukacsko eta!. ........... 514/162
`5,037,815 A
`8/1991 Lukacsko eta!. ........... 514/653
`5,043,358 A
`4/1993 Goldman et a!.
`........... 424/489
`5,204,118 A
`11/1993 Lukacsko eta!. ........... 514/471
`5,260,333 A
`................. 424/52
`11/1994 Singer et a!.
`5,364,616 A
`12/1994 Fawzi eta!. ................ 514/570
`5,373,022 A
`........... 424/464
`5/1995 Goldman et a!.
`5,417,980 A
`11/1995 Stables ....................... 514/161
`5,466,436 A
`5/1996 Mandel ....................... 514/33
`5,514,663 A
`5/1997 Mandel et a!. .............. 424/456
`5,631,022 A
`7/1997 Breitner eta!. ............. 514/570
`5,643,960 A
`11/1997 Keirn et a!. ................. 424/452
`5,686,105 A
`2/1998 Halskov et a!. ............. 424/682
`5,716,648 A
`9/1999 Lichtenberger eta!. ....... 514/78
`5,955,451 A
`1!2000 Lundberg et a!. ........... 424/468
`6,013,281 A
`2/2000 Breitner eta!. ............. 514/570
`6,025,395 A
`12/2000 Ohannesian eta!. ........ 514/629
`6,160,020 A
`12/2000 Bohlin eta!. ............... 514/338
`6,162,816 A
`3/2001 Gustavsson et a!. ........ 424/464
`6,207,188 B1
`4/2002 Depui et a!. ................ 424/469
`6,365,184 B1
`5!2002 Flanagan et a!.
`........... 424/479
`6,395,298 B1
`11/2002 Flanagan et a!.
`........... 424/479
`6,485,747 B1
`4/2003 Chen et a!. ................. 424/469
`6,544,556 B1
`9/2001 Barbe rich et a!.
`. ... ... 546/273.7
`2001!0025107 A1
`11/2001 Scott et a!.
`................. 424/463
`2001!0036473 A1
`11/2001 Gelber eta!. ................. 514/27
`2001!0044410 A1
`......... 424/400
`1!2002 Lunde berg et a!.
`2002/0012676 A1
`4/2002 Yelle eta!. ................. 514/338
`2002/0042433 A1
`4/2002 Cherukuri et a!. .......... 424/459
`2002/0044962 A1
`4/2002 Chen . ... ... ... .. ... ... ... ... .. ... 435/6
`2002/0045184 A1
`7/2002 Lundberg eta!. ........ 424/184.1
`2002/0086029 A1
`8/2002 Bergman eta!. ............ 514/338
`2002/0111370 A1
`10/2002 Depui et a!. ................ 424/452
`2002/0155153 A1
`1!2003 Barbe rich et a!.
`. . . . . . . . . . 514/338
`2003/0008903 A1
`6/2003 Lundberg et a!. ........... 424/474
`2003/0113375 A1
`7/2003 Chen et a!. ................. 424/470
`2003/0129235 A1
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`GB
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`
`0 426 479 A1
`5/1991
`0 550 083 B1
`7/1993
`2 105 193
`3/1983
`wo 85/03443
`8/1985
`wo 93/12817
`7/1993
`wo 94/07541
`4/1994
`wo 98/22117
`5/1998
`wo 99/00380
`1!1999
`wo 99/12524
`3/1999
`wo 00/71122
`11/2000
`WO 00/72838 A1
`12/2000
`WO 03/017980 A1
`3/2003
`01HER PUBLICATIONS
`
`......... A61K/31!415
`A61K/31!34
`A61K/31!34
`A61K/45/06
`A61K/45/06
`A61K/49/00
`A61K/33/24
`. .. ... ... C07D/401!12
`............ A61K/9/20
`.......... A61K/31!44
`.......... A61K/31!04
`A61K/9/16
`
`Bigard, et al., "Complete Prevention by Omeprazole of
`Aspirin Induced Gastric Lesions in Healthy Subjects," GUT
`29(5):A712, T49 (1988).
`Bombardier, et al., "Comparison of Upper Gastrointestinal
`Toxicity of Rofecoxib and Naproxen in Patients with Rheu(cid:173)
`matoid Arthritis," N. Engl. J. Med. 343:1520-1528 (2000).
`Brown, et al., "Prevention of the Gastrointestinal Adverse
`Effects of Nonsteroidal Anti-Inflammatory Drugs," Pract.
`Drug Safety 21:503-512 (1999).
`Cullen, et al., "Primary Gastroduodenal Prophylaxis with
`Omeprazole for Non-Steroidal Anti-Inflammatory Drug
`Users," Aliment. Pharmacal. Ther. 12:135-140 (1998).
`
`Hawkey, "Progress in Prophylaxis Against Nonsteroidal
`Anti-Inflammatory Drug-Associated Ulcers and Erosions,"
`Am. J. Med. 104:67S-74S (1998).
`Hawkey, et al., "Omeprazole Compared with Misoprostol
`for Ulcers Associated with Nonsteroidal Anti-Inflammatory
`Drugs," N. Engl. J. Med. 338:727-734 (1998).
`Katz, et al., "Gastric Acidity and Acid Breakthrough with
`Twice-Daily Omeprazole or Iansoprazole," Aliment. Phar(cid:173)
`macal. Ther 14:709-714 (2000).
`Kephart, et al., "Coprescribing of Nonsteroidal Anti-Inflam(cid:173)
`matory Drugs and Cytoprotective and Antiulcer Drugs in
`Nova Scotia's Senior Population," Clin. Ther. 17:1159-1173
`(1995).
`Lad, et al., "Management of Nonsteroidal Anti-Inflamma(cid:173)
`tory Drug-Induced Gastroduodenal Disease by Acid Sup(cid:173)
`pression," Can. J. Gastroenterol13:135-142 (1999).
`Mattsson, et al., "Omeprazole Provides Protection Against
`Experimentally Induced Gastric Mucosal Lesions," Eur. J.
`Pharmacal. 91:111-114 (1983).
`Oddsson, et al., "Endoscopic Findings in the Stomach and
`Duodenum after Treatment with Enteric-Coated and Plain
`Naproxen Tablets in Healthy Subjects," Scand. J. Castro(cid:173)
`enteral. 25:231-234 (1990).
`Scheiman, "NSAlD-Induced Peptic Ulcer Disease: A Criti(cid:173)
`cal Rview of Pathogenesis and Management," Dig. Dis.
`12:210-222 (1994).
`Selway, "Potential Hazards of Long-Term Acid Suppres(cid:173)
`sion," Scand. J. Gasatroenterol. 25(Supp. 178):85-92
`(1990).
`Silverstein, et al., "Gastrointestinal Toxicity with Celecoxib
`vs. Nonsteroidal Anti-Inflammatory Drugs for Osteoarthri(cid:173)
`tis and Rheumatoid Arthritis; The CLASS Study: A Ran(cid:173)
`domized Controlled Trial," JAMA 284:1247-1255 (2000).
`Tronstad, et al., "Gastroscopic Findings after Treatment with
`Enteric-Coated and Plain Naproxen Tablets in Healthy
`Subjects," Scand. J. Gastroenterol. 20:239-242 (1985).
`Wolfe, et al., "Gastrointestinal Toxicity of Nonsteroidal
`Anti-Inflammatory Drugs,"
`N.
`Engl.
`J. Med.
`340:1888-1899 (1999).
`Yeomans, et al., "A Comparison of Omeprazole with Ran(cid:173)
`itidine for Ulcers Associated with Nonsteroidal Anti-In(cid:173)
`flammatory Drugs," N. Engl. J. Med. 338:719-726 (1998).
`Yeomans, et al., "New Data on Healing of Nonsteroidal
`Anti-Inflammatory Drug-Associated Ulcers and Erosions,"
`Am. J. Med. 104:56S-61S (1998).
`English language abstract for DE 198 01811, Reference B13
`above.
`Dent, "Why Proton Pump Inhibition Should Heal and Pro(cid:173)
`tect Against Nonsteroidal Anti-Inflammatory Drug Ulcers,"
`Am. J. Med. 104:52S-55S (1998) .
`Kimmey, et al., "Role of H2-Receptor Blockers in the
`Prevention of Gastric Injury Resulting from Nonsteroidal
`Anti-inflammatory Agents," Am. J. Med. 84:49-52 (1988) .
`Lee, et al., "Omeprazole Prevents Indomethacin-Induced
`Gastric Ulcers in Rabbits," Aliment. Pharmacal. Ther.
`10:571-576 (1996).
`Lichtenbergetr, et al., "Nonsteroidal Anti-inflammatory
`Drug and Phospholipid Prodrugs: Combination Therapy
`with Antisecretory Agents in Rats," Gastroenterology
`111:990-995 (1996).
`Savarino, et al., "Effect of One-Month Treatment with
`Nonsteroidal Antiinflammatory Drugs (NSAlDs) on Gastric
`pH of Rheumatoid Arthritis Patients," Digestive Diseases
`and Sciences 43:459-463 (1998).
`Wagner, et al., "Effects of Nonsteroidal Antiinflammatory
`Drugs on Ulcerogenesis and Gastric Secretion in Pylorus(cid:173)
`Ligated Rat," Digestive Diseases and Sciences 40:134--140
`(1995).
`
`MYLAN PHARMS. INC. EXHIBIT 1004 PAGE 2
`
`

`

`

`

`U.S. Patent
`
`Aug. 9, 2005
`
`Sheet 2 of 2
`
`US 6,926,907 B2
`
`NAPROXEN
`SODIUM
`PELLET
`
`ENTERIC FILM
`COAT
`FIG.3
`
`MYLAN PHARMS. INC. EXHIBIT 1004 PAGE 4
`
`

`

`US 6,926,907 B2
`
`1
`PHARMACEUTICAL COMPOSITIONS FOR
`THE COORDINATED DELIVERY OF NSAIDS
`
`CROSS REFERENCE TO RELATED
`APPLICATIONS
`
`The present application claims priority to U.S. provisional
`application No. 60/294,588, filed on Jun. 1, 2001.
`
`FIELD OF THE INVENTION
`
`The present invention is directed to pharmaceutical com(cid:173)
`positions that provide for the coordinated release of an acid
`inhibitor and a non-steroidal anti-inflammatory drug
`(NSAID). These compositions have a reduced likelihood of
`causing unwanted side effects, especially gastrointestinal
`side effects, when administered as a treatment for pain,
`arthritis and other conditions amenable to treatment with
`NSAIDs.
`
`BACKGROUND OF THE INVENTION
`
`Although non-steroidal anti-inflammatory drugs are
`widely accepted as effective agents for controlling pain, their
`administration can lead to the development of gastroduode(cid:173)
`nal lesions, e.g., ulcers and erosions, in susceptible indi(cid:173)
`viduals. It appears that a major factor contributing to the
`development of these lesions is the presence of acid in the
`stomach and upper small intestine of patients. This view is
`supported by clinical studies demonstrating an improvement
`in NSAID tolerability when patients are also taking inde(cid:173)
`pendent doses of acid inhibitors (Dig. Dis. 12:210--222
`(1994); Drug Safety 21:503-512 (1999); Aliment. Pharma(cid:173)
`cal. Ther. 12:135-140 (1998); Am. J. Med. 104(3A)
`:67S-74S (1998); Clin. Ther. 17:1159-1173 (1995)). Other
`major factors contributing to NSAID-associated gastropathy
`include a local toxic effect of NSAIDs and inhibition of
`protective prostaglandins (Can. J. Gastraenteral. 13:
`135-142 (1999) and Pract. Drug Safety 21:503-512,
`(1999)), which may also make some patients more suscep(cid:173)
`tible to the ulcerogenic effects of other noxious stimuli.
`In general, more potent and longer lasting acid inhibitors,
`such as proton pump inhibitors, are thought to be more
`protective during chronic administration of NSAIDs than
`shorter acting agents, e.g., histamine H2 receptor antagonists
`(H-2 blockers) (N. Eng. J. Med. 338:719-726 (1998);Am. J.
`Med. 104(3A):56S-61S (1998)). The most likely explana(cid:173)
`tion for this is that gastric pH fluctuates widely throughout
`the dosing interval with short acting acid inhibitors leaving
`the mucosa vulnerable for significant periods of time. In
`particular, the pH is at its lowest point, and hence the mucosa
`is most vulnerable, at the end of the dosing interval (least
`amount of acid inhibition) and for some time after the
`subsequent dose of acid inhibitor. In general, it appears that
`when a short acting acid inhibitor and an NSAID are
`administered simultaneously, NSAID-related mucosal dam(cid:173)
`age occurs before the pH of the gastrointestinal tract can be
`raised and after the acid inhibiting effect of the short acting
`acid inhibitor dissipates.
`Although longer lasting agents, such as proton pump
`inhibitors (PPis), usually maintain a consistently higher
`gastroduodenal pH throughout the day, after several days
`dosing, their antisecretory effect may be delayed for several
`hours and may not take full effect for several days (Clin.
`Pharmacakinet. 20:38-49 (1991)). Their effect may be
`diminished toward the end of the usual dosing interval.
`Intragastric pH rises particularly slowly with the first dose in
`a course of treatment since this class of drugs is enteric
`
`10
`
`15
`
`2
`coated to avoid destruction by stomach acid. As a result,
`absorption is delayed for several hours. Even then, some
`patients fail to respond consistently to drugs of this type and
`suffer from "acid breakthrough" which again leaves them
`5 vulnerable to NSAID-associated gastroduodenaldamage
`(Aliment. Pharmacal. Ther. 14:709-714 (2000)). Despite a
`significant reduction in gastroduodenal lesions with the
`concomitant administration of a proton pump inhibitor dur(cid:173)
`ing six months of NSAID therapy, up to 16% of patients still
`develop ulcers, indicating that there remains substantial
`room for improvement (N. Eng. J. Med. 338:727-734
`(1998)). Thus, the addition of a pH sensitive enteric coating
`to an NSAID could provide additional protection against
`gastroduodenal damage not provided by the H2 blocker or
`PPI alone. In addition, although long acting acid inhibitors
`may reduce the risk of GI lesions in chronic NSAID users,
`there are questions about the safety of maintaining an
`abnormally elevated pH in a patient's GI tract for a pro(cid:173)
`longed period of time (Scand. J. Gastraenteral. Suppl.
`20 178:85-92 (1990)).
`Recognizing the potential benefits of PPis for the preven(cid:173)
`tion of NSAID-induced gastroduodenal damage, others have
`disclosed strategies for combining the two active agents for
`therapeutic purposes. However, these suggestions do not
`25 provide for coordinated drug release or for reducing intra(cid:173)
`gastric acid levels to a non-toxic level prior to the release of
`NSAID (U.S. Pat. Nos. 5,204,118; 5,417,980; 5,466,436;
`and 5,037,815). In certain cases, suggested means of deliv(cid:173)
`ery would expose the gastrointestinal tract to NSAIDs prior
`30 to onset of PPI activity (U.S. Pat. No. 6,365,184).
`Attempts to develop NSAIDs that are inherently less toxic
`to the gastrointestinal tract have met with only limited
`success. For example, the recently developed
`cyclooxygenase-2 (COX-2) inhibitors show a reduced ten-
`35 dency to produce gastrointestinal ulcers and erosions, but a
`significant risk is still present, especially if the patient is
`exposed to other ulcerogens (JAMA 284:1247-1255 (2000);
`N. Eng. J. Med. 343:1520-1528 (2000)). In this regard, it
`appears that even low doses of aspirin will negate most of
`40 the benefit relating to lower gastrointestinal lesions. In
`addition, the COX-2 inhibitors may not be as effective as
`other NSAIDs at relieving some types of pain and have been
`associated with significant cardiovascular problems (JADA
`131:1729-1737 (2000); SCRIP2617, pg. 19, Feb. 14, 2001);
`45 NY Times, May 22, 2001, pg. C1)).
`Other attempts to produce an NSAID therapy with less
`gastrointestinal toxicity have involved the concomitant
`administration of a cytoprotective agent. In 1998, Searle
`began marketing Arthrotecâ„¢ for the treatment of arthritis in
`50 patients at risk for developing GI ulcers. This product
`contains misopristol (a cytoprotective prostaglandin) and the
`NSAID diclofenac. Although patients administered Arthro(cid:173)
`tecâ„¢ do have a lower risk of developing ulcers, they may
`experience a number of other serious side effects such as
`55 diarrhea, severe cramping and, in the case of pregnant
`women, potential damage to the fetus.
`Another approach has been to produce enteric coated
`NSAID products. However, even though these have shown
`modest reductions in gastroduodenal damage in short term
`60 studies (Scand. J. Gastraenteral. 20: 239-242 (1985) and
`Scand. J. Gastraenteral. 25:231-234 (1990)), there is no
`consistent evidence of a long term benefit during chronic
`treatment.
`Overall, it may be concluded that the risk of inducing GI
`65 ulcers is a recognized problem associated with the admin(cid:173)
`istration of NSAIDs and that, despite considerable effort, an
`ideal solution has not yet been found.
`
`MYLAN PHARMS. INC. EXHIBIT 1004 PAGE 5
`
`

`

`3
`SUMMARY OF THE INVENTION
`
`US 6,926,907 B2
`
`4
`release of NSAID is delayed until after the pH in the GI tract
`has risen. In a preferred embodiment, the unit dosage form
`is a multilayer tablet, having an outer layer comprising the
`acid inhibitor and an inner core which comprises the
`5 NSAID. In the most preferred form, coordinated delivery is
`accomplished by having the inner core surrounded by a
`polymeric barrier coating that does not dissolve unless the
`surrounding medium is at a pH of at least 3.5, preferably at
`least 4 and more preferably, at least 5. Alternatively, a barrier
`10 coating may be employed which controls the release of
`NSAID by time, as opposed to pH, with the rate adjusted so
`that NSAID is not released until after the pH of the gas(cid:173)
`trointestinal tract has risen to at least 3.5, preferably at least
`4, and more preferably at least 5. Thus, a time-release
`15 formulation may be used to prevent the gastric presence of
`NSAID until mucosal tissue is no longer exposed to the
`damage enhancing effect of very low pH.
`The invention includes methods of treating a patient for
`pain, inflammation and/or other conditions by administering
`20 the pharmaceutical compositions described above. Although
`the method may be used for any condition in which an
`NSAID is effective, it is expected that it will be particularly
`useful in patients with osteoarthritis or rheumatoid arthritis.
`Other conditions that may be treated include, but are not
`25 limited to: all form of headache, including migraine head(cid:173)
`ache; acute musculoskeletal pain; ankylosing spondylitis;
`dysmenorrhoea; myalgias; and neuralgias.
`In a more general sense, the invention includes methods
`of treating pain, inflammation and/or other conditions by
`orally administering an acid inhibitor at a dose effective to
`raise a patient's gastric pH to at least 3.5, preferably to at
`least 4 or and more preferably to at least 5. The patient is also
`administered an NSAID, for example in a coordinated
`dosage form, that has been coated in a polymer that only
`dissolves at a pH of least 3.5, preferably at least 4 and, more
`preferably, 5 or greater or which dissolves at a rate that is
`slow enough to prevent NSAID release until after the pH has
`been raised. When acid inhibitor and NSAID are adminis-
`40 tered in separate doses, e.g., in two separate tablets, they
`should be given concomitantly (i.e., so that their biological
`effects overlap) and may be given concurrently, i.e., NSAID
`is given within one hour after the acid inhibitor. Preferably,
`the acid inhibitor is an H2 blocker and, in the most preferred
`embodiment, it is famotidine at a dosage of between 5 mg
`and 100 mg. Any of the NSAIDs described above may be
`used in the method but naproxen at a dosage of between 200
`and 600 mg is most preferred. It is expected that the inhibitor
`an~ analgesic will be typically delivered as part of a single
`umt dosage form which provides for the coordinated release
`50 of therapeutic agents. The most preferred dosage form is a
`multilayer tablet having an outer layer comprising an H2
`blocker and an inner core comprising an NSAID.
`The. inve~tion al~o provides a method for increasing
`55 compliance m a patient requiring frequent daily dosing of
`NSAIDs by providing both an acid inhibitor and NSAID in
`a single convenient, preferably coordinated, unit dosage
`form, thereby reducing the number of individual doses to be
`administered during any given period.
`
`30
`
`35
`
`The present invention is based upon the discovery of a
`new method for reducing the risk of gastrointestinal side
`effects in people taking NSAIDs for pain relief and for other
`conditions, particularly during chronic treatment. The
`method involves the administration of a single, coordinated,
`u~it-d~se produ~t that combines: a) an agent that actively
`raises mtragastnc pH to levels associated with less risk of
`NSAID-induced ulcers; and b) an NSAID that is specially
`formulated to be released in a coordinated way that mini(cid:173)
`mizes the adverse effects of the NSAID on the gastroduode(cid:173)
`nal mucosa. Either short or long acting acid inhibitors can be
`effectively used in the dosage forms. This method has the
`added benefit of being able to protect patients from other
`gastrointestinal ulcerogens whose effect may otherwise be
`enhanced by the disruption of gastroprotective prostaglan(cid:173)
`dins due to NSAID therapy.
`In. its first aspect, the invention is directed to a ph arm a(cid:173)
`ceutlcal composition in unit dosage form suitable for oral
`administration to a patient. The composition contains an acid
`inhibitor present in an amount effective to raise the gastric
`pH of a patient to at least 3.5, preferably to at least 4, and
`more preferably to at least 5, when one or more unit dosage
`forms are administered. The gastric pH should not exceed
`7.5 and preferably should not exceed 7.0. The term "acid
`inhibitor" refers to agents that inhibit gastric acid secretion
`and increase gastric pH. In contrast to art teaching against
`the use of H2 blockers for the prevention of NSAID(cid:173)
`associated ulcers (N. Eng. J. Med. 340: 1888-1899 (1999)),
`these agents are preferred compounds in the current inven(cid:173)
`tion. Specific, H2 blockers that may be used include
`cimetidine, ranitidine, ebrotidine, pabutidine, lafutidine,
`loxtidine or famotidine. The most preferred acid inhibitor is
`famotidine present in dosage forms in an amount of between
`? mg and 100 mg. Other agents that may be effectively used
`mclude proton pump inhibitors such as omeprazole,
`esomeprazole, pantoprazole, lansoprazole or rabeprazole.
`The pharmaceutical composition also contains a non(cid:173)
`steroidal anti-inflammatory drug in an amount effective to
`reduce or eliminate pain or inflammation. The NSAID may
`be a COX-2 inhibitor such as celecoxib
`rofecoxib
`meloxicam, piroxicam, valdecoxib, parecoxib, etoricoxib:
`CS-502, JTE-522, L-745,337 or NS398. Alternatively, the
`NS~ID may be aspirin, acetaminophen, ibuprofen,
`flurb1profen, ketoprofen, naproxen, oxaprozin, etodolac,
`indomethacin, ketorolac, lornoxicam, nabumetone, or
`diclofenac. The most preferred NSAID is naproxen in an
`amount of between 50 mg and 1500 mg, and more
`preferably, in an amount of between 200 mg and 600 mg. It
`will be understood that, for the purposes of the present
`invention, reference to an acid inhibitor, NSAID, or anal(cid:173)
`gesic agent will include all of the common forms of these
`compounds and, in particular, their pharmaceutically accept(cid:173)
`able salts. The amounts of NSAIDs which are therapeuti(cid:173)
`cally effective may be lower in the current invention than
`otherwise found in practice due to potential positive kinetic
`interaction and NSAID absorption in the presence of an acid
`inhibitor.
`The term "unit dosage form" as used herein refers to a 60
`single entity for drug administration. For example, a single
`tablet or capsule combining both an acid inhibitor and an
`NSAID would be a unit dosage form. A unit dosage form of
`the present invention preferably provides for coordinated
`drug release, in a way that elevates gastric pH and reduces 65
`the deleterious effects of the NSAID on the gastroduodenal
`mucosa, i.e., the acid inhibitor is released first and the
`
`45
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 is a schematic diagram of a four layer tablet dosage
`form. There is a naproxen core layer surrounded by a barrier
`layer. A third, enteric coating, layer delays the release of
`naproxen sodium until the pH is at a specific level, e.g.,
`above 4. Finally, there is an outer layer that releases an acid
`inhibitor such as famotidine.
`
`MYLAN PHARMS. INC. EXHIBIT 1004 PAGE 6
`
`

`

`US 6,926,907 B2
`
`10
`
`20
`
`25
`
`5
`FIG. 2 illustrates a three layer dosage form. An acid
`inhibitor, e.g., famotidine, is released immediately after
`ingestion by a patient in order to raise the pH of the
`gastrointestinal tract to above a specific pH, e.g., above 4.
`The innermost layer contains naproxen. Thus, the dosage 5
`form has a naproxen core, an enteric film coat and an acid
`inhibitor film coat.
`FIG. 3 illustrates a naproxen sodium pellet which contains
`a subcoat or barrier coat prior to the enteric film coat.
`DETAILED DESCRIPTION OF THE
`INVENTION
`The present invention is based upon the discovery of
`improved pharmaceutical compositions for administering
`NSAIDs to patients. In addition to containing one or more
`NSAIDs, the compositions include acid inhibitors that are 15
`capable of raising the pH of the GI tract of patients. All of
`the dosage forms are designed for oral delivery and provide
`for the coordinated release of therapeutic agents, i.e., for the
`sequential release of acid inhibitor followed by analgesic.
`The NSAIDs used in preparations may be either short or
`long acting. As used herein, the term "long acting" refers to
`an NSAID having a pharmacokinetic half-life of at least 2
`hours, preferably at least 4 hours and more preferably, at
`least 8-14 hours. In general, its duration of action will equal
`or exceed about 6-8 hours. Examples of long-acting
`NSAIDs are: fiurbiprofen with a half-life of about 6 hours;
`ketoprofen with a half-life of about 2 to 4 hours; naproxen
`or naproxen sodium with half-lives of about 12 to 15 hours
`and about 12 to 13 hours respectively; oxaprozin with a half
`life of about 42 to 50 hours; etodolac with a half-life of about
`7 hours; indomethacin with a half life of about 4 to 6 hours;
`ketorolac with a half-life of up to about 8-9 hours, nabu(cid:173)
`metone with a half-life of about 22 to 30 hours; mefenamic
`acid with a half-life of up to about 4 hours; and piroxicam
`with a half-life of about 4 to 6 hours. If an NSAID does not 35
`naturally have a half-life sufficient to be long acting, it can,
`if desired, be made long acting by the way in which it is
`formulated. For example, NSAIDs such as acetaminophen
`and aspirin may be formulated in a manner to increase their
`half-life or duration of action. Methods for making appro(cid:173)
`priate formulations are well known in the art (see e.g.
`Remington's Pharmaceutical Sciences, 16'h ed., A. Oslo
`editor, Easton, Pa. (1980)).
`It is expected that a skilled pharmacologist may adjust the
`amount of drug in a pharmaceutical composition or admin(cid:173)
`istered to a patient based upon standard techniques well
`known in the art. Nevertheless, the following general guide(cid:173)
`lines are provided:
`Indomethacin is particularly useful when contained in
`tablets or capsules in an amount from about 25 to 75
`mg. A typical daily oral dosage of indomethacin is three
`25 mg doses taken at intervals during the day. However,
`daily dosages of up to about 150 mg are useful in some
`patients.
`Aspirin will typically be present in tablets or capsules in
`an amount of between about 250 mg and 1000 mg.
`Typical daily dosages will be in an amount ranging
`from 500 mg to about 10 g.
`Ibuprofen may be provided in tablets or capsules of 50, 60
`100, 200, 300, 400, 600, or 800 mg. Daily doses should
`not exceed 3200 mg. 200 mg-800 mg may be particu(cid:173)
`larly useful when given 3 or 4 times daily.
`Flurbiprofen is useful when in tablets at about from 50 to
`100 mg. Daily doses of about 100 to 500 mg, and 65
`particularly from about 200 to 300 mg, are usually
`effective.
`
`6
`Ketoprofen is useful when contained in tablets or capsules
`in an amount of about 25 to 75 mg. Daily doses of from
`100 to 500 mg and particularly of about 100 to 300 mg
`are typical as is about 25 to 50 mg every six to eight
`hours.
`Naproxen is particularly useful when contained in tablets
`or capsules in an amount of from 250 to 500 mg. For
`naproxen sodium, tablets of about 275 or about 550 mg
`are typically used. Initial doses of from 100 to 1250 mg,
`and particularly 350 to 800 mg are also used, with
`doses of about 550 mg being generally preferred.
`Oxaprozin may be used in tablets or capsules in the range
`of roughly 200 mg to 1200 mg, with about 600 mg
`being preferred. Daily doses of 1200 mg have been
`found to be particularly useful and daily doses should
`not exceed 1800 mg or 26 mg/kg.
`Etodolac is useful when provided in capsules of 200 mg
`to 300 mg or in tablets of about 400 mg. Useful doses
`for acute pain are 200--400 mg every six-eight hours,
`not to exceed 1200 mg/day. Patients weighing less than
`60 kg are advised not to exceed doses of 20 mg/kg.
`Doses for other uses are also limited to 1200 mg/day in
`divided doses, particularly 2, 3 or 4 times daily.
`Ketorolac is usefully provided in tablets of 1-50 mg, with
`about 10 mg being typical. Oral doses of up to 40 mg,
`and particularly 10-30 mg/day have been useful in the
`alleviation of pain.
`Nabumetone may be provided in tablets or capsules of
`between 500 mg and 750 mg. Daily doses of
`1500-2000 mg, after an initial dose of 100 mg, are of
`particular use.
`Mefenamic acid is particularly useful when contained in
`tablets or capsules of 50 mg to 500 mg, with 250 mg
`being typical. For acute pain, an initial dosage of
`1-1000 mg, and particularly about 500 mg, is useful,
`although other doses may be required for certain
`patients.
`Lomoxicam is provided in tablets of 4 mg or 8 mg. Useful
`doses for acute pain are 8 mg or 16 mg daily, and for
`arthritis are 12 mg daily.
`One particular group of long acting NSAIDs that may be
`used are the cyclooxygenase-2 inhibitors. These include:
`celecoxib, rofecoxib, meloxicam, piroxicam, valdecoxib,
`45 parecoxib, etoricoxib, CS-502, JTE-522, L-745,337, or
`NS398. JTE-522, L-745,337 and NS398 as described, inter
`alia, in Wakatani, et al. (Jpn. J. Pharmacal. 78:365-371
`(1998)) and Panara, et al. (Br. J. Pharmacal. 116:2429-2434
`(1995)). The amount present in a tablet or administered to a
`50 patient will depend upon the particular COX-2 inhibitor
`being used. For example:
`Celecoxib may be administered in a tablet or capsule
`containing from about 100 mg to about 500 mg or,
`preferably, from about 100 mg to about 200 mg.
`Piroxicam may be used in tablets or capsules containing
`from about 10 to 20 mg.
`Rofecoxib will typically be provided in tablets or capsules
`in an amount of 12.5, 25 or 50 mg. The recommended
`initial daily dosage for the management of acute pain is
`50 mg.
`Meloxicam is provided in tablets of 7.5 mg, with a
`recommended daily dose of 7.5 or 15 mg for the
`management of osteoarthritis.
`Valdecoxib is provided in tablets of 10 or 20 mg, with a
`recommended daily dose of 10 mg for arthritis or 40 mg
`for dysmenorrhea.
`
`30
`
`40
`
`55
`
`MYLAN PHARMS. INC. EXHIBIT 1004 PAGE 7
`
`

`

`US 6,926,907 B2
`
`7
`With respect to acid inhibitors, tablets or capsules may
`contain anywhere from 1 mg to as much as 1 g. Typical
`amounts for H2 blockers are: cimetidine, 100 to 800 mg/unit
`dose; ranitidine, 50-300 mg/unit dose; famotidine, 5-100
`mg/unit dose; ebrotidine 400-800 mg/unit dose; pabutidine 5
`40 mg/unit dose; lafutidine 5-20 mg/unit dose; and
`nizatidine, 50-600 mg/unit dose. Proton pump inhibitors
`will typically be present at about 5 mg to 600 mg per unit
`dose. For example, the proton pump inhibitor omeprazole
`should be present in tablets or capsules in an amount from 10
`5 to 50 mg, with about 20 mg per unit dosage form being
`preferred. Other typical amounts are: esomeprazole, 5-100
`mg, with about 40 mg per unit dosage form being preferred;
`lansoprazole, 15-150 mg, with about 30 mg per unit dosage
`form being preferred; pantoprazole, 10--200 mg, with about 15
`40 mg per unit dosage form being preferred; and
`rabeprazole, 5-100 mg, with about 20 mg per unit dosage
`form being preferred.
`Making of Pharmaceutical Preparations
`The pharmaceutical compositions of the invention include 20
`tablets, dragees, liquids and capsules and can be made in
`accordance with methods that are standard in the art (see,
`e.g., Remington's Pharmaceutical Sciences, 16'h ed., A Oslo
`editor, Easton, Pa. (1980)). Drugs and drug combinations
`will typically be prepared in admixture with conventional 25
`excipients. Suitable carriers include, but are not limited to:
`water; salt solutions; alcohols; gum arabic; vegetable oils;
`benzyl alcohols; polyethylene glycols; gelatin; carbohy(cid:173)
`drates such as lactose, amylose or starch; magnesium stear(cid:173)
`ate; talc; silicic acid; paraffin; perfume oil; fatty acid esters; 30
`hydroxymethylcellulose; polyvinyl pyrrolidone; etc. The
`pharmaceutical preparations can be sterilized and, if desired,
`mixed with auxiliary agents such as: lubricants,
`preservatives, disintegrants; stabilizers; wetting agents;
`emulsifiers; salts; buffers; coloring agents; flavoring agents; 35
`or aromatic substances.
`Enteric coating layer(s) may be applied onto the core or
`onto the barrier layer of the core using standard coating
`techniques. The enteric coating materials may be dissolved
`or dispersed in organic or aqueous solvents and may include 40
`one or more of the following materials: methacrylic acid
`copolymers, shellac, hydroxypropylmethcellulose phthalate,
`polyvinyl acetate phthalate, hydroxypropylmethylcellulose
`trimellitate, carboxymethylethylcellulose, cellulose acetate
`phthalate or other suitable enteric coating polymer(s). The 45
`pH at which the enteric coat will dissolve can be controlled
`by the polymer or combination of polymers selected and/or
`ratio of pendant groups. For example, dissolution charac(cid:173)
`teristics of the polymer film can be altered by the ratio of free
`carboxyl groups to ester groups. Enteric coating layers also 50
`contain pharmaceutically acceptable plasticizers such as
`triethyl citrate, dibutyl phthalate, triacetin, polyethylene
`glycols, polysorbates or other plasticizers. Additives such as
`dispersants, colorants, anti-adhering and anti-f

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket